Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2002 7
2003 7
2004 11
2005 14
2006 11
2007 14
2008 19
2009 11
2010 12
2011 23
2012 20
2013 15
2014 19
2015 28
2016 25
2017 23
2018 22
2019 22
2020 21
2021 15
2022 10
2023 4
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Results by year

Filters applied: . Clear all
Page 1
A novel type-2 innate lymphoid cell-based immunotherapy for cancer.
Saranchova I, Xia CW, Besoiu S, Finkel PL, Ellis SLS, Kari S, Munro L, Pfeifer CG, Fazli L, Gleave ME, Jefferies WA. Saranchova I, et al. Among authors: gleave me. Front Immunol. 2024 Mar 7;15:1317522. doi: 10.3389/fimmu.2024.1317522. eCollection 2024. Front Immunol. 2024. PMID: 38524132 Free PMC article.
DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2.
Kaarijärvi R, Kaljunen H, Nappi L, Fazli L, Kung SHY, Hartikainen JM, Paakinaho V, Capra J, Rilla K, Malinen M, Mäkinen PI, Ylä-Herttuala S, Zoubeidi A, Wang Y, Gleave ME, Hiltunen M, Ketola K. Kaarijärvi R, et al. Among authors: gleave me. Commun Biol. 2024 Jan 18;7(1):108. doi: 10.1038/s42003-023-05741-x. Commun Biol. 2024. PMID: 38238517 Free PMC article.
High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker.
Liu S, Hawley SJ, Kunder CA, Hsu EC, Shen M, Westphalen L, Auman H, Newcomb LF, Lin DW, Nelson PS, Feng Z, Tretiakova MS, True LD, Vakar-Lopez F, Carroll PR, Simko J, Gleave ME, Troyer DA, McKenney JK, Brooks JD, Liss MA, Stoyanova T. Liu S, et al. Among authors: gleave me. Sci Rep. 2024 Jan 4;14(1):486. doi: 10.1038/s41598-023-50215-z. Sci Rep. 2024. PMID: 38177207 Free PMC article.
Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells.
Yenki P, Bhasin S, Liu L, Nabavi N, Cheng CW, Tam KJ, Peacock JW, Adomat HH, Tombe T, Fazli L, Ivanova L, Dusek C, Khosravi S, Guns EST, Wang Y, Buttyan R, Gleave ME, Ong CJ. Yenki P, et al. Among authors: gleave me. Endocr Relat Cancer. 2023 Nov 6;30(12):e230010. doi: 10.1530/ERC-23-0010. Print 2023 Dec 1. Endocr Relat Cancer. 2023. PMID: 37800655 Free PMC article.
Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression.
Zhang F, Biswas M, Massah S, Lee J, Lingadahalli S, Wong S, Wells C, Foo J, Khan N, Morin H, Saxena N, Kung SHY, Sun B, Parra Nuñez AK, Sanchez C, Chan N, Ung L, Altıntaş UB, Bui JM, Wang Y, Fazli L, Oo HZ, Rennie PS, Lack NA, Cherkasov A, Gleave ME, Gsponer J, Lallous N. Zhang F, et al. Among authors: gleave me. Nucleic Acids Res. 2023 Jan 11;51(1):99-116. doi: 10.1093/nar/gkac1158. Nucleic Acids Res. 2023. PMID: 36535377 Free PMC article.
Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study.
Schenk JM, Liu M, Neuhouser ML, Newcomb LF, Zheng Y, Zhu K, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Wagner AA, Lin DW. Schenk JM, et al. Among authors: gleave me. Nutr Cancer. 2023;75(2):618-626. doi: 10.1080/01635581.2022.2143537. Epub 2022 Nov 7. Nutr Cancer. 2023. PMID: 36343223 Free PMC article.
307 results